XPR1 and cancer: Figure 4A shows the significantly increased expression of SLC16A3, SLC53A1, SLC25A32, and SLC2A3 in cancer tissues compared to normal tissues. The immunohistochemistry results, depicted in the right panel of Figure 4A, further confirm the elevated protein levels of these SLCs in cancer tissues, providing visual evidence that supports the differential expression observed in the RNA-seq data.